Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

November 6th 2024

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC

November 6th 2024

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

November 5th 2024

Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.

Selinexor May Confer PFS Benefit in TP53 Wild-Type Endometrial Cancer

November 4th 2024

David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.

A Call to Action: Determining Optimal Dose, Schedule, and Appropriate Modifications for Antineoplastic Pharmaceutical Agents

November 4th 2024

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches

October 31st 2024

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC

October 29th 2024

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Uproleselan Plus Chemotherapy Fails to Improve EFS in Older Patients With AML

October 29th 2024

Uproleselan plus 7+3 chemotherapy failed to improve EFS vs chemotherapy alone in older patients with newly diagnosed AML fit for intensive chemotherapy.

Novel HPK1 Inhibitor NDI-101150 Shows Early Activity in RCC

October 29th 2024

Anita Scheuber, MD, PhD, details the mechanism of action of NDI-101150, early data seen with the agent, and next steps in the HPK1 inhibitor’s investigation.

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

October 28th 2024

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

October 28th 2024

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

October 28th 2024

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

October 28th 2024

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

October 25th 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

October 25th 2024

A panel of experts detail updated data and developments in the advanced renal cell carcinoma space with immunotherapy-based combination regimens.

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

October 24th 2024

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

October 24th 2024

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.